Dabrafenib, Trametinib Beneficial in Resected Melanoma

This article originally appeared here.
Share this content:
Dabrafenib, Trametinib Beneficial in Resected Melanoma
Dabrafenib, Trametinib Beneficial in Resected Melanoma

TUESDAY, Sept. 12, 2017 (HealthDay News) -- For patients with resected stage III melanoma with BRAF V600E or V600K mutations, adjuvant dabrafenib plus trametinib is associated with a higher rate of relapse-free survival, according to a study published online Sept. 10 in the New England Journal of Medicine. The research was published to coincide with the European Society of Medical Oncology Congress, held from Sept. 8 to 12 in Madrid.

Georgina V. Long, M.B., B.S., Ph.D., from the University of Sydney, and colleagues randomized 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations to receive oral dabrafenib plus trametinib (438 patients) or two matched placebo tablets (432 patients) for 12 months.

The researchers found that the estimated three-year rate of relapse-free survival was 58 percent in the combination-therapy group and 39 percent in the placebo group at a median follow-up of 2.8 years (hazard ratio for relapse or death, 0.47; 95 percent confidence interval, 0.39 to 0.58; P < 0.001). The three-year overall survival rate was 86 and 77 percent in the combination-therapy and placebo groups (hazard ratio for death, 0.57; 95 percent confidence interval, 0.42 to 0.79; P = 0.0006); this did not cross the prespecified interim analysis boundary of P = 0.000019. The combination-therapy group had higher rates of distant metastasis-free survival and freedom from relapse.

"The adjuvant use of dabrafenib plus trametinib resulted in a significantly lower rate of recurrence than the adjuvant use of placebo," the authors write.

The study was funded by GlaxoSmithKline and Novartis; Novartis manufactures dabrafenib and trametinib.

Abstract
Full Text (subscription or payment may be required)
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »